
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne is a global life science tools company that appears to be well-positioned for future growth, with a strong presence in the protein sciences and diagnostics and genomics segments. The company has a diverse customer base and a strong international presence, providing stability and potential for growth. Additionally, Bio-Techne has taken steps to improve profitability by divesting its Exosome Diagnostics business and consolidating its brands. These efforts, combined with the potential for increased demand and margin expansion, make Bio-Techne a promising investment opportunity.
Bears say
Bio-Techne is facing market share headwinds in its protein sciences and diagnostics and genomics segments, as larger companies with comparator offerings are difficult to compete with. The company is also facing challenges in its cell therapy platform due to a decline in orders from two primary customers, resulting in a 50% year-over-year decline in specific order volumes. While management has maintained its full-year guidance for LSD organic growth, it may be difficult to achieve due to continued headwinds and the delayed impact of the cell therapy air pocket.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares